Monday-Friday, 8:00 AM-5:00 PM
(904) 893-3265
When mood stabilizers help with stability but the depressive lows keep returning, TMS therapy for bipolar depression may be another option to consider. It uses targeted magnetic pulses to stimulate mood-regulating brain circuits involved in the depressive phase, without adding another daily medication.
56 studies
reviewed confirming TMS is efficacious and safe for bipolar depression
47% response rate and 27% remission rate
across pooled clinical studies
20–36 sessions
over 4-6 weeks, 19-37 minutes per session
Off-label use
with FDA breakthrough status (not FDA-cleared for bipolar)
Here is the important distinction. TMS is not FDA-cleared specifically for bipolar disorder. It is FDA-cleared for conditions such as major depressive disorder, OCD, anxious depression, and smoking cessation. For bipolar depression, use remains off-label, although breakthrough device designation signals that the FDA sees enough promise to support faster review.
That said, clinical evidence is strong. A 2025 systematic review and meta-analysis of 56 studies (representing 1,709 patients with bipolar depression) concluded that TMS is efficacious and safe for bipolar depression, with response and remission rates on par with unipolar depression.
The best candidates for TMS in bipolar depression are:
Adults with Bipolar I or Bipolar II experiencing a major depressive episode
Patients who have failed at least one adequately dosed bipolar depression treatment
Those on a stable anti-manic medication regimen (lithium, valproate, lamotrigine, or atypical antipsychotics)
Patients without active mania, hypomania, or rapid cycling at treatment initiation
Critical safety finding: In a clinical study of 17 patients with bipolar treatment-resistant depression who received TMS, no manic or hypomanic episodes occurred during any patient’s course of treatment. However, patients must be on a stable mood stabilizer regimen.
TMS for bipolar depression is typically episode-focused intervention, designed to treat an acute depressive episode.
FitMind treats bipolar disorder as part of comprehensive psychiatric care. Victoria Kozel, DNP and Dr. Sarah Boaz will evaluate your bipolar type, medication regimen, and current mood state to determine if TMS is appropriate.
Bipolar depression is not just “regular depression” in someone with bipolar disorder. It has different treatment risks, different medication considerations, and a higher need for mood monitoring. Some patients also experience mixed features, where depressive symptoms appear alongside agitation, restlessness, or hypomanic energy. Here is how the depressive phase often shows up:
Symptom Domain
Depressed mood
Loss of interest
Fatigue
Psychomotor changes
Sleep problems
Concentration
Guilt and worthlessness
Hopelessness
Mixed features
Suicidal thoughts
Common Impact
Heavy, hollow, or irritable. Not just sad, sometimes just angry at everything
Things you loved feel pointless. Hobbies, sex, friends. None of it lands
Waking up exhausted after 10 hours. Moving through wet cement all day
Either slowed down (moving like molasses) or agitated (can’t sit still, pacing, picking)
Can’t fall asleep, wake at 3 AM, or sleep 12 hours and still feel exhausted
Can’t read a paragraph. Can’t follow a conversation. Brain fog that won’t lift
Feeling like a burden. Like you’ve failed everyone. The shame is crushing
The belief that nothing will ever feel different. Not suicidal necessarily. Just done
Energy is up but mood is down. Agitated, irritable, restless, but not happy
Passive wish to not wake up. Active planning requires emergency care
TMS targets the left dorsolateral prefrontal cortex (DLPFC), a brain region involved in mood regulation. In depression (both unipolar and bipolar), this region tends to be underactive. High-frequency stimulation wakes it up, and over time, this strengthens connections to deeper mood-regulating areas.
The 2025 meta-analysis found that both high-frequency protocols on the left DLPFC and low-frequency protocols on the right DLPFC are robustly associated with positive outcomes in bipolar depression. Newer protocols like intermittent theta burst stimulation (iTBS) were also found to be effective and noninferior to standard high-frequency rTMS.
Think of it like nudging a mood circuit that has gone quiet. The magnetic pulses are temporary, but the goal is longer-lasting neuroplastic change, helping the brain strengthen healthier regulation patterns over time.
A 2023 case report described a 68-year-old female with Bipolar II Disorder and a four-month medication-refractory major depressive episode with mixed features. After just 9 daily sessions of left DLPFC TMS using the NeuroStar system, her depression score dropped from 32 to 2 (MADRS), and her mania score dropped from 22 to 0 (YMRS).
TMS does not work through the bloodstream. That means it avoids common medication-like side effects such as weight gain, sexual dysfunction, and daytime drowsiness. No sedation is required, and most patients can drive home after treatment.
Here’s how TMS stacks up against the alternatives for bipolar depression:
Feature
Works by
FDA status for bipolar depression
Mania risk
Systemic side effects
Response rate for bipolar depression
Anesthesia required
Driving afterward
TMS Therapy (off-label)
Magnetic pulses rebalancing prefrontal circuits
Off-label; breakthrough status
Low (zero cases in 17-patient study with stabilizers)
None
47%
No
Yes
Mood Stabilizers (Lithium, Lamotrigine)
Multiple mechanisms (GSK-3, sodium channels, etc.)
Approved for maintenance and acute mania/depression
Low (protective)
Weight gain, tremor, thyroid/kidney issues, sedation
Variable (maintenance, not acute)
No
Yes
Antidepressants (SSRIs)
Increasing serotonin availability
Not recommended as monotherapy (can induce mania)
High, can trigger switch
Weight gain, sexual dysfunction, emotional blunting
Not recommended
No
Yes
ECT
Controlled seizure under anesthesia
Approved for severe, treatment-resistant depression including bipolar
Low with proper anesthesia
Memory loss, confusion, anesthesia
50-70%
Yes
No
TMS for bipolar depression follows a similar structure to depression treatment, but with one major safety requirement: your mood must be stable enough, and your anti-manic regimen should already be in place.
Step 1:
Free TMS Education
You meet with patient coordinator Valeria Alana to discuss your bipolar type (I or II), current mood state (depressed? stable? mixed?), medication regimen, and prior treatment history.
Step 2:
Psychiatric Evaluation
Dr. Sarah Boaz or Victoria Kozel, DNP confirms bipolar diagnosis, screens for mixed features or rapid cycling, and verifies you’re on a stable anti-manic regimen. TMS is not appropriate if you’re actively manic, hypomanic, or rapid cycling.
Step 3:
Motor threshold mapping + First Treatment.
Motor threshold mapping + First Treatment.
About 90 minutes. The TMS treater finds the exact pulse strength needed for your brain. Your first visit takes about 90 minutes total. This includes:
Step 4:
Daily Sessions
20-36 sessions total over 4-6 weeks, 5 days per week. Each session lasts 19-37 minutes. You sit in a recliner, awake the whole time. The target is the left DLPFC (standard protocol). The 2025 meta-analysis found that longer treatment courses (more sessions) predict greater antidepressant effect.
Step 5 :
Return to Normal Activity
No sedation or recovery period is required. Most patients return to normal routines after each session and continue mood stabilizers exactly as prescribed.
Most people notice changes gradually. The meta-analysis found that higher baseline illness severity predicted greater treatment response.
2025 Systematic Review and Meta-Analysis (Ventura et al.): Published in Biological Psychiatry Global Open Science, this review analyzed 56 articles representing 1,709 patients with bipolar depression.
Clinical study (Phillips et al., Journal of Psychiatric Practice, 2020): Retrospective analysis of 71 patients (17 with bipolar TRD, 54 with unipolar TRD) treated between 2008-2017. No manic or hypomanic episodes occurred during any patient’s course of TMS treatment. Both groups showed similar patterns of depression response over treatment time. (1)
Mixed episode case report (Beydler et al., Frontiers in Psychiatry, 2023): A 68-year-old female with Bipolar II Disorder and a four-month medication-refractory major depressive episode with mixed features (MADRS=32, YMRS=22) received 9 daily sessions of left DLPFC TMS. Her MADRS dropped to 2 and YMRS to 0. The patient reported feeling “great”, stable with minimal depression and hypomania for the first time in years. (2)
Insurance coverage for TMS in bipolar depression can be complicated.
Because TMS is not FDA-cleared specifically for bipolar disorder, many insurers may classify bipolar depression treatment as off-label or investigational. Coverage often depends on the patient’s diagnosis history, plan rules, and documentation of medical necessity.
However, many patients with bipolar disorder also have documented treatment-resistant major depressive disorder during depressive episodes (which IS FDA-cleared). FitMind works with your insurance to establish medical necessity based on your full clinical picture.
Insurance coverage requirements for TMS generally include:
A diagnosis covered by your plan (most commonly depression or OCD)
A history of trying other first-line treatments without adequate relief, such as 2-4 antidepressants
Evidence of psychotherapy, either completed or ongoing
No history of seizures or certain neurological conditions
FitMind accepts:
Aetna
Blue Cross Blue Shield (BCBS)
Cigna
Humana
UnitedHealthcare
Medicare
TRICARE
Before you start TMS for bipolar depression, you must have:
A confirmed diagnosis of Bipolar I or Bipolar II (by psychiatric evaluation)
A stable anti-manic medication regimen (lithium, valproate, lamotrigine, or atypical antipsychotic)
No active mania, hypomania, or rapid cycling (mixed episodes may be eligible)
Failed at least one adequate trial of bipolar depression treatment
Yes, TMS may be worth discussing if antidepressants caused mood instability, agitation, rapid cycling, or did not help enough. In bipolar depression, antidepressants are not usually recommended as standalone treatment because they can increase switching risk in some patients, especially without mood stabilizer protection.
TMS works differently. Instead of changing serotonin through the bloodstream, it uses magnetic pulses to stimulate mood-regulating brain circuits. That makes it a non-systemic option for bipolar depression treatment, but it still needs psychiatric monitoring and a stable mood-stabilizing plan.
TMS may be considered when PTSD symptoms remain after first-line treatments such as trauma-focused therapy, SSRIs, or medication management. This is often described as TMS for treatment-resistant PTSD, especially when trauma symptoms overlap with depression, anxiety, sleep disruption, or emotional numbness.
The goal is not to replace psychotherapy or erase trauma memories. TMS as adjunctive PTSD treatment may help reduce baseline hyperarousal, mood symptoms, and stress reactivity so patients can function better and tolerate trauma-focused work more effectively.
Mood stabilizers help protect against manic or hypomanic switching. TMS is generally well tolerated in bipolar depression studies, but bipolar disorder itself carries a switching risk, especially when depression begins to lift or energy improves faster than mood stability.
You should not stop lithium, lamotrigine, valproate, or an atypical antipsychotic before TMS unless your psychiatrist tells you to. TMS is usually considered adjunctive care, meaning it supports your bipolar depression treatment plan rather than replacing mood-stabilizing medication.
The available evidence suggests the risk is low when patients are carefully screened and maintained on appropriate mood-stabilizing treatment. In the 2025 meta-analysis, rates of treatment-emergent mania or hypomania were low and similar to sham treatment.
That said, “low risk” does not mean “no risk.” During TMS, your provider should monitor for warning signs like reduced need for sleep, racing thoughts, impulsivity, irritability, pressured speech, or unusually elevated energy.
The strongest evidence supports stimulation of the dorsolateral prefrontal cortex, especially high-frequency left DLPFC and low-frequency right DLPFC protocols. The 2025 meta-analysis also found that iTBS appeared noninferior to standard high-frequency rTMS protocols.
In plain language, there may not be one single “best” protocol for every patient. Protocol choice may depend on your diagnosis, symptom severity, treatment history, session availability, device type, and whether your provider is prioritizing speed, tolerability, or prior response patterns.
TMS has been studied more broadly in bipolar depression, including patients with Bipolar I and Bipolar II, but the evidence is still developing. A 2023 case report described a patient with Bipolar II depression with mixed features who improved after left DLPFC TMS, with both depression and hypomania scores dropping substantially.
That case is promising, but it should not be treated like a guarantee. Mixed features require extra caution because the patient may feel depressed and activated at the same time, which means mood monitoring is just as important as symptom improvement.
A typical TMS course for bipolar depression often follows the same general rhythm as depression treatment: sessions five days per week for several weeks. Many protocols involve around 20 to 36 sessions, depending on the clinic, protocol, and patient response.
The 2025 meta-analysis found that longer treatment courses predicted greater antidepressant effect. That means stopping too early may reduce the chance of meaningful improvement, especially for patients with more severe or long-lasting bipolar depressive episodes.
This is one of the most important bipolar-specific concerns. Sometimes energy, sleep, or motivation can shift before mood fully stabilizes. In bipolar disorder, that can be helpful, but it can also be a warning sign if it comes with agitation, impulsivity, irritability, or decreased need for sleep.
Tell your provider quickly if you feel “wired,” unusually confident, restless, or like your thoughts are moving too fast. TMS treatment for bipolar depression should include mood tracking, not just depression score tracking.
Often, not directly. Because TMS for bipolar depression is still off-label, many insurers may classify it as investigational for that specific diagnosis. Coverage is more likely when the patient also has a covered diagnosis such as treatment-resistant major depressive disorder or another FDA-cleared indication.
That does not mean you should assume it is impossible. A clinic can review your benefits, diagnosis history, medication trials, and documentation of medical necessity before treatment begins. For bipolar depression, coverage usually depends on the exact plan and clinical picture.
Not everyone responds. The 2025 meta-analysis reported a pooled response rate of 47.2% and remission rate of 27.1%, which means many patients improve, but many also do not reach full response or remission.
If TMS does not work enough, your psychiatrist may discuss protocol changes, medication adjustments, maintenance strategies, ECT for severe or urgent cases, or other emerging options. A non-response does not mean you failed; it means the treatment plan needs to be recalibrated.
TMS is mainly being studied and used for the depressive phase of bipolar disorder, not as a primary treatment for mania. The strongest current clinical angle is TMS for bipolar depression, especially when depressive symptoms remain despite adequate medication treatment.
If you are actively manic, hypomanic, or rapidly cycling, TMS may not be appropriate at that moment. Stabilizing mood comes first, then TMS can be considered if depressive symptoms remain persistent and disabling.
Bipolar depression can be harder to treat than unipolar depression, especially when depressive episodes continue despite mood stabilizers. TMS offers a non-systemic, evidence-supported option to discuss with your provider, with research showing a 47% pooled response rate and low mood-switching risk when patients are carefully screened and monitored.
Call or text (904) 893-3265 to schedule your free consultation. Same-week appointments are often available.
13241 Bartram Park Blvd Ste 613, Jacksonville, FL 32258
Depression can make it difficult to enjoy the things you love in life, but there is hope for a better future. If your depression symptoms have not responded to your attempts at treatment, NeuroStar Advanced TMS Therapy in Jacksonville may be a good fit for you.
Our providers at FitMind Therapeutics are here to help. Schedule a consultation with our team today to determine whether TMS is the next step in your treatment plan.
Please include the following minimal patient information: first/last name, DOB, address, contact number/email, diagnosis, insurance and policy number, and name of referring provider.
TMS therapy is typically covered by most major insurance plans for the treatment of Major Depressive Disorder (MDD). If you're unsure whether your insurance covers your treatment, please contact us, and we'll be happy to verify your benefits on your behalf. For conditions that are not covered by insurance, we'll work with you to discuss alternative treatment and payment options.
